By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Sign In
Time puterTime puter
Aa
  • Home
  • Social Media
  • Softwares
  • Gadgets
  • Mobiles
  • Solution
  • Apple
  • News
  • Contact Us!
Reading: Sarepta shares leap on FDA’s eteplirsen overview delay
Share
Time puterTime puter
Aa
Search
  • Home
  • Social Media
  • Softwares
  • Gadgets
  • Mobiles
  • Solution
  • Apple
  • News
  • Contact Us!
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Time puter > Solution > Sarepta shares leap on FDA’s eteplirsen overview delay
Solution

Sarepta shares leap on FDA’s eteplirsen overview delay

Deep
Last updated: 2016/06/18 at 10:35 AM
Deep Published June 18, 2016
Share
2 Min Read

biotech pharmaceuticals

stocks of Sarepta Therapeutics rose nearly 27 percent Wednesday after announcing the meals and Drugadministration is delaying its evaluate of a key drug made through the company.

The FDA notified Sarepta that “they are persevering with their evaluation and internal discussions related to our pending NDA for eteplirsen and will now not have the ability to complete their work by the Prescription Drug person price Act (PDUFA) purpose date of may additionally 26, 2016,” Sarepta said, in a announcement. “The FDA has communicated that they’ll keep to paintings past the PDUFA purposedate and attempt to complete their work in as well timed a way as feasible.”

In a statement, the FDA said:

“As cited inside the organisation‘s assertion, the FDA contacted Sarepta Therapeutics to let themunderstand we’re continuing necessary paintings on their New Drug software for eteplirsen and couldno longer take action via the purpose date. We can not comment further at the drug review, howeveryou can contact the business enterprise for extra information. The FDA is prohibited by way of lawfrom commenting on pending packages due to the fact such statistics is taken into consideration privateand proprietary to the applicant.”
Eteplirsen is a drug designed by means of Sarepta to treat Duchenne Muscular Dystrophy.

Finish
TAGGED: delay, eteplirsen, FDA's, leap, on, overview:, Sarepta, shares

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.
[mc4wp_form]
By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Deep June 18, 2016
Share
Previous Article college students easy lecture rooms in place of giving re-examination
Next Article IIHM eCHAT exam 2016: check out the results now

Recent Post

  • The Consequences of Ignoring Pregnancy Cravings: Potential Risks and Challenges
  • Navigating Pregnancy After Abdominoplasty: Considerations and Precautions
  • Managing Itchy Breasts During Pregnancy: Causes and Solutions
  • Understanding Eye Twitching During Pregnancy
  • Blessed with a Bundle of Joy: Our Family is Growing!
  • Surprising Dad on Father’s Day with the Best Gift Ever: A New Baby!
  • The Benefits of Using Spider Tape for Pregnancy Support and Comfort
  • Cakes to announce pregnancy: Baby on the Way and a Cake to Match!
Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc..

[mc4wp_form]
Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?